Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.47 |
| ▸ | NPY1R | P25929 | 9/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.47 |
| ▸ | NPY2R | P49146 | 5/20 | 0.47 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.42 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30974056 | 0.91 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30582929 | 0.91 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31571454 | 0.89 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30389828 | 0.89 | FNTA (0.41) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30903462 | 0.88 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30596211 | 0.87 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30946719 | 0.87 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2RNMUR2 | |
| SCHEMBL30197694 | 0.86 | NOD1 (0.40) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29774197 | 0.85 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30090904 | 0.84 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748447-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4241785-B1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260001918-A1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4241785-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-116162175-A | Influenza virus vaccine and application thereof | 西奈山伊坎医学院 | 2023-05-26 | — | — | CN | disclosed |
| EP-2758075-B1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001918-A1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | CD44, SIGLEC7, SIGLEC9 | NPY4R 3117/4885NPY1R 3267/4885NPY5R 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.